Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Study in Phase II to Evaluate Efficacy of Initial R-CHOP Combination in Folicular Lymphoma no Treated Previously. Consolidation w Ith One Dose of 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

NCT00662948 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT00662948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00662948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Study in Phase II to Evaluate Efficacy of Initial R-CHOP Combination in Folicular Lymphoma no Treated Previously. Consolidation w Ith One Dose of 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2008
Completion date
October 30, 2017
Enrollment
149 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma